Treatment of Rapidly Progressive Glomerulonephritis in Lupus Nephritis (Diffuse Proliferative, Class IV)
Clinical Scenario
This protocol addresses patients with lupus nephritis presenting as rapidly progressive glomerulonephritis — specifically those with diffuse proliferative lupus nephritis (class IV, and select class III cases) in whom renal function is declining rapidly.
Underlying Condition
Diffuse proliferative lupus nephritis (class IV, and some class III) is associated with a high risk of rapid renal function decline when it manifests as RPGN. In this setting, adding immunosuppressive agents to corticosteroids in the initial regimen has been shown to improve renal function and survival.
Treatment Approach (Overview)
Initial management involves corticosteroids combined with an immunosuppressive agent. When the decline in renal function is very rapid, or when severe systemic complications are present, an escalated corticosteroid approach is incorporated alongside the immunosuppressive backbone.
The full regimen — including agent selection, sequencing, and escalation criteria — is detailed in the structured protocol.
References
DOI: 10.1007/s10157-015-1218-8
- We recommend immunosuppressive agents (cyclophosphamide or mycophenolate mofetil) with corticosteroids as the initial therapy for patients with diffuse proliferative lupus nephritis.
- In patients with lupus nephritis presenting with RPGN (class IV and some class III cases), the addition of immunosuppressive agents to corticosteroids in the initial therapy has been shown to improve renal function and survival.
- In patients with lupus nephritis presenting with RPGN (class IV and some class III cases), adding intravenous pulse corticosteroid therapy to oral corticosteroids is recommended when the decline of renal function is very rapid, or when severe systemic complications such as pulmonary hemorrhage or central nervous system (CNS) lupus are present.
- The standard protocol in pulse corticosteroid therapy is intravenous administration of 500 mg to 1 g of methylprednisolone for three consecutive days, followed by 0.6–0.8 mg/kg body weight of oral prednisolone.
View source ↗